Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes

V E Murphy, V L Clifton, P G Gibson

Exacerbations of asthma during pregnancy represent a significant clinical problem and may be related to poor pregnancy outcomes. A systematic review of the literature was conducted for publications related to exacerbations during pregnancy. Four studies with a control group (no asthma) and two groups of women with asthma (exacerbation, no exacerbation) were included in meta-analyses using fixed effects models. During pregnancy, exacerbations of asthma which require medical intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.

Women who have a severe exacerbation during pregnancy are at a significantly increased risk of having a low birth weight baby compared with women without asthma. No significant associations between exacerbations during pregnancy and preterm delivery or pre-eclampsia were identified. Inhaled corticosteroid use may reduce the risk of exacerbations during pregnancy. Pregnant women may be less likely to receive oral steroids for the emergency intervention occur in about 20% of women, with approximately 6% of women being admitted to hospital. Exacerbations during pregnancy occur primarily in the late second trimester; the major triggers are viral infection and non-adherence to inhaled corticosteroid medication.
exacerbations which resulted in medical interventions such as hospitalisation, unscheduled visits to a doctor, or the use of emergency treatment. In the multicentre study by Schatz et al,7 as many as 20% of women had exacerbations of asthma requiring medical intervention, even among a group of women with actively managed asthma. There are currently no studies which have examined less severe exacerbations or compared exacerbations of different severities.

It has been suggested that one third of women experience worsening asthma during pregnancy, one third have no change, and one third have an improvement in asthma during pregnancy.4 One study showed that pregnant women with asthma who felt their asthma was unchanged, 2% were hospitalised and 17% visited the emergency department.7 These data suggest that even women who report improvements in asthma may require medical intervention for asthma during pregnancy. The concept that only one third of women experience worsening asthma may underestimate the risk of having an asthma exacerbation during pregnancy.

### Risk factors for exacerbations

Severe asthma appears to be the biggest risk factor for exacerbations during pregnancy.4 Several studies have shown that the exacerbation rate increases with increasing asthma severity.4 17 20 Few studies have systematically assessed the risk factors of exacerbations during pregnancy, although some have noted that respiratory viral infections may have been involved. Pregnant women may be more susceptible to viral infection because of changes in cell mediated immunity during pregnancy which may lead to exacerbations of asthma.4 One study showed that pregnant women with asthma were more likely to have an upper respiratory tract or urinary tract infection during pregnancy (35%) than pregnant women without asthma (5%), and that severe asthma was associated with significantly more infections than mild asthma.25 Viral infection is likely to be an important trigger

---

### Table 1 Summary of studies investigating the incidence of asthma exacerbations during pregnancy

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Year</th>
<th>Study design</th>
<th>Asthma (n)</th>
<th>% hospitalised</th>
<th>% ED visits</th>
<th>ICS use</th>
<th>Suspected causes of exacerbation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Williams et al</td>
<td>UK</td>
<td>1955-65</td>
<td>Case series</td>
<td>n=23</td>
<td>100%</td>
<td></td>
<td></td>
<td>Nil (nasorespiratory infection)</td>
</tr>
<tr>
<td>Gluck and Gluck et al</td>
<td>USA</td>
<td>1986-9</td>
<td>Case series</td>
<td>n=47</td>
<td>28%</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Stenius-Aarniala et al</td>
<td>Finland</td>
<td>1972-82</td>
<td>Prospective cohort</td>
<td>n=198</td>
<td>17%</td>
<td></td>
<td></td>
<td>Some used ICS (up to a maximum dose of 400 µg/day)</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1978-84</td>
<td>Prospective cohort</td>
<td>n=330</td>
<td>1.8%</td>
<td>10.9%</td>
<td>10% used beclomethasone</td>
<td>Discontinuation of medication, viral infection</td>
</tr>
<tr>
<td>Apter et al</td>
<td>USA</td>
<td>1978-88</td>
<td>Case series</td>
<td>n=28</td>
<td>64%</td>
<td>43%</td>
<td></td>
<td>Discontinuation of medication, viral infection</td>
</tr>
<tr>
<td>Mabie et al</td>
<td>USA</td>
<td>1986-9</td>
<td>Case series</td>
<td>n=200</td>
<td>42.5%</td>
<td>13%</td>
<td></td>
<td>Nil</td>
</tr>
<tr>
<td>Perlow et al</td>
<td>USA</td>
<td>1985-90</td>
<td>Historical cohort</td>
<td>n=81</td>
<td>46%</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Jana et al</td>
<td>India</td>
<td>1983-92</td>
<td>Prospective cohort</td>
<td>n=182</td>
<td>8.2%</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1978-89</td>
<td>Prospective cohort</td>
<td>n=486</td>
<td>11.1% received nebulised bronchodilators in clinic or ED</td>
<td>3%</td>
<td></td>
<td>ICS use by 34% of those who had an exacerbation and 62% of those who did not have an exacerbation</td>
</tr>
<tr>
<td>Stenius-Aarniala et al</td>
<td>Finland</td>
<td>1982-92</td>
<td>Prospective and retrospective cohort</td>
<td>n=504</td>
<td>6.5%</td>
<td></td>
<td></td>
<td>Lack of ICS use</td>
</tr>
<tr>
<td>Dombrowski et al</td>
<td>USA</td>
<td>1992-5</td>
<td>Historical cohort</td>
<td>n=54</td>
<td>43%</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Kurzczuk et al</td>
<td>Australia</td>
<td>1995-7</td>
<td>Cross sectional survey</td>
<td>n=79</td>
<td>62% had an &quot;asthma attack or wheezing&quot; during pregnancy</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Henderson et al</td>
<td>USA</td>
<td>1960-5</td>
<td>Prospective cohort</td>
<td>n=1574</td>
<td>2.2%</td>
<td></td>
<td></td>
<td>Nil</td>
</tr>
<tr>
<td>Hartt et al</td>
<td>USA</td>
<td>1985-93</td>
<td>Historical cohort</td>
<td>n=2461</td>
<td>6% (during influenza season)</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1994-9</td>
<td>Prospective cohort</td>
<td>n=1739 overall</td>
<td>51.5% overall</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1994-9</td>
<td>Prospective cohort</td>
<td>n=873 mild</td>
<td>2.3% mild</td>
<td></td>
<td></td>
<td>28% used beclomethasone</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1994-9</td>
<td>Prospective cohort</td>
<td>n=814 moderate</td>
<td>6.8% moderate</td>
<td></td>
<td></td>
<td>8% used beclomethasone</td>
</tr>
<tr>
<td>Schatz et al</td>
<td>USA</td>
<td>1994-9</td>
<td>Prospective cohort</td>
<td>n=52 severe</td>
<td>26.9% severe</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Namazy et al</td>
<td>USA</td>
<td>1996-2002</td>
<td>Case series</td>
<td>n=451</td>
<td>7.6% had an &quot;acute attack&quot;</td>
<td></td>
<td></td>
<td>100% ICS use</td>
</tr>
<tr>
<td>Mantel et al</td>
<td>Canada</td>
<td>1990-2000</td>
<td>Nésted case-control study</td>
<td>n=3315</td>
<td>13% ED or admission</td>
<td></td>
<td></td>
<td>46% used ICS</td>
</tr>
<tr>
<td>Carroll et al</td>
<td>USA</td>
<td>1995-2001</td>
<td>Historical cohort</td>
<td>n=4315</td>
<td>6.3%</td>
<td>11.1%</td>
<td></td>
<td>16% used ICS without OCS</td>
</tr>
<tr>
<td>Bolhavares et al</td>
<td>North America</td>
<td>1998-2003</td>
<td>Prospective cohort</td>
<td>n=654</td>
<td>2.5%</td>
<td></td>
<td></td>
<td>55.3%</td>
</tr>
<tr>
<td>Otsuka et al</td>
<td>Japan</td>
<td>1987-2003</td>
<td>Historical cohort</td>
<td>n=592</td>
<td>1.38% had &quot;asthma attacks&quot; during labour and delivery</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>Schatz and Lieberman</td>
<td>USA</td>
<td>2000-1</td>
<td>Historical cohort</td>
<td>n=633</td>
<td>0.2%</td>
<td>3.8%</td>
<td></td>
<td>16% before pregnancy, 10% during pregnancy</td>
</tr>
<tr>
<td>Murphy et al</td>
<td>Australia</td>
<td>1997-2003</td>
<td>Prospective cohort</td>
<td>n=146</td>
<td>8.2%</td>
<td>2.7%</td>
<td></td>
<td>Viral infection, non-adherence to ICS</td>
</tr>
</tbody>
</table>

ED, emergency department; ICS, inhaled corticosteroid; OCS, oral corticosteroid.
for asthma exacerbations during pregnancy, although no studies have identified the viruses responsible.

Atopy does not appear to be a risk factor for exacerbations during pregnancy, with one study reporting a higher exacerbation rate among women with non-atopic asthma. Carroll et al. examined racial differences in the incidence of asthma exacerbations during pregnancy in a low income population in USA and found that the proportion of hospital admissions, emergency department presentations, and use of rescue oral steroids for asthma during pregnancy was significantly higher among blacks than whites, possibly due to inadequate prenatal care.

A major contributor to exacerbations during pregnancy is the lack of appropriate treatment with inhaled corticosteroids (ICSs). Many early studies reporting high rates of exacerbation were conducted before the introduction of ICS medication. In 1996 Stenius-Aarniala et al. found that the risk of having an exacerbation was reduced by over 75% among women who were using ICS regularly. This was supported by data from a recent study which found an increase in asthma related emergency department and physician visits during pregnancy among women who did not use ICS before pregnancy. Improvements in asthma management which address these issues and reduce the exacerbation rate are needed.

Timing of exacerbations during pregnancy
Exacerbations can occur at any time during gestation, but tend to cluster around the late second trimester. Gluck and Gluck found that the onset of exacerbations was normally distributed around 6 months gestation, with no exacerbations occurring before the fourth month. A prospective cohort study of 504 pregnant women with asthma found that the gestational age of onset of exacerbations was normally distributed, with the majority occurring between 17 and 24 weeks gestation (mean 20.8 weeks). Similar results were reported by Murphy et al., with exacerbations normally distributed from 9 to 39 weeks gestation around a mean of 20.8 weeks. Acute attacks of asthma during labour are rare. This is consistent with studies showing that asthma is more likely to improve during the third trimester. Stenius-Aarniala et al. found that 14% of patients with atopic asthma and 22% of patients with non-atopic asthma experienced asthma symptoms during labour, which were mild and well controlled by inhaled β2 agonists. Similar data have been reported by other groups. Jana et al. noted that none of their patients commenced labour during an acute asthma attack. A recent multicentre study found that 18% of women had asthma symptoms during labour, of those with severe asthma, 46% experienced symptoms during labour.

Confounders
A large proportion of pregnant women with asthma smoke and it is unclear whether this increases the risk for exacerbations during pregnancy. One study reported a higher rate of smoking among women who had an exacerbation of asthma (19% vs 11% of women who did not have an exacerbation), although the difference was not statistically significant. Murphy et al. found a similar rate of smoking among women who had a severe exacerbation and those without an exacerbation during pregnancy (25%). Some studies have been conducted in populations of low socioeconomic status or in women with additional medical complications including chronic hypertension, diabetes and obesity, while other studies have been conducted in women with actively managed asthma who may be less likely to experience exacerbations during pregnancy. Few studies have adequately controlled for confounding factors.

Association between asthma exacerbations and adverse perinatal outcomes
There have been conflicting data on the association between asthma exacerbations and adverse pregnancy or fetal outcomes (table 2). Several studies have found that exacerbations of asthma during pregnancy are associated with low birth weight, pre-eclampsia, and perinatal mortality. However, other well designed prospective cohort studies have found no significant relationships between asthma exacerbations during pregnancy and poor perinatal outcomes, including preterm delivery, pre-eclampsia and low birth weight, in women with actively managed asthma.

Low birth weight
A study from Saudi Arabia found a lower mean birth weight and placental weight among a group of women with asthma, of whom 70% had an emergency department presentation, compared with a non-asthmatic control group. These women were living at high altitude which may have amplified the effect of asthma exacerbations on fetal hypoxia. In a series of 80 pregnancies complicated by severe asthma, mean birth weight was 434 g lower in women with at least one episode of status asthmaticus requiring emergency treatment than in women who did not require emergency treatment during pregnancy. The authors concluded that, even when oral steroids were used, prevention of status asthmaticus may prevent a reduction in fetal growth, suggesting that the asthma exacerbation itself—rather than the medication used to treat it—may play an important role in this mechanism.

Jana et al. studied 182 pregnancies in Indian women with asthma and found that 15 had severe asthma during pregnancy which required hospitalisation. Approximately half of these women had a low birth weight neonate and mean birth weight was significantly reduced by 369 g compared with the women who were not hospitalised, where birth weights were similar to the non-asthmatic control group. A recent prospective cohort study from Australia found that women who had a severe exacerbation during pregnancy requiring medical intervention were at increased risk of reduced male birth weight.

Preterm delivery
The effect of asthma exacerbations on reduced fetal growth is independent of any changes in gestational age at delivery. Several studies which reported reduced birth weight among mothers with exacerbations during pregnancy did not find any increase in the rate of preterm delivery in these women. However, other studies found an association between oral steroid use and preterm delivery. An historical cohort study of 81 women who all required medication use for asthma found that oral steroid dependent asthmatics were much more likely to have an admission for asthma (71%) than non-steroid dependent asthmatics (30%), and were at greater risk of preterm labour and delivery (54%) and preterm premature rupture of membranes. The risk of preterm delivery may have been associated with the use of oral steroids, as described in more recent studies, or may have been due to the exacerbation itself.

Pre-eclampsia and pregnancy induced hypertension (PIH)
Stenius-Aarniala et al. found that mild pre-eclampsia was three times higher in pregnant women who were hospitalised for asthma than in women with asthma who did not experience an exacerbation during pregnancy. This finding may have been confounded by the fact that women who were hospitalised had blood pressure recorded more often than
other women and therefore may have been more likely to receive a diagnosis. A larger study from this group found no effect of exacerbations on pregnancy outcomes including pre-eclampsia, gestational diabetes, premature rupture of membranes, preterm delivery, perinatal death, and birth weight. In a case-control study Martel et al. found that exacerbations during pregnancy had no significant effect on the risk of PIH or pre-eclampsia. However, women who had admissions or emergency department visits for asthma before the pregnancy were at significantly increased risk of both PIH and pre-eclampsia, suggesting that the underlying severity of asthma may be important.

**Perinatal mortality**

In 1970 Gordon et al. studied 277 patients with actively treated asthma, of which 16 had severe asthma characterised by regular acute attacks or status asthmaticus during pregnancy. Six of the 16 women who had exacerbations of asthma had either a spontaneous abortion, fetal death, or neonatal death. This study was conducted before the introduction of ICS medication.

In an historical cohort study, Hartert et al. examined acute cardiopulmonary hospitalisations during the influenza season among pregnant women in the USA. Of the 297 women who were hospitalised, approximately half had asthma. Although the effect of hospitalisation on perinatal outcomes was not specifically examined in women with asthma, it was noted that there were three stillbirths among the women who were hospitalised, all from mothers with asthma.

**META-ANALYSES**

Meta-analyses were conducted to test the hypothesis that asthma exacerbations are associated with the adverse pregnancy outcomes low birth weight, preterm delivery and pre-eclampsia. The meta-analyses conformed to standard methodological guidelines. Studies were identified by searching Pubmed and EMBASE databases for English language publications with the search term “asthma and pregnancy” as described in the introduction. Studies were hand searched and included if data were available from a control group without asthma and where two groups of women with asthma were described (exacerbation, no exacerbation). Studies also had to describe either the number of low birth weight infants (<2500 g), or the number of preterm deliveries (<37 completed weeks gestation), or the number of women with pre-eclampsia in each study group. Pre-eclampsia was defined as an increase in blood pressure noted after the 20th week of gestation (systolic blood pressure >140 and/or diastolic blood pressure >90 mm Hg) in the presence of proteinuria (>0.3 g/l).

The relative risk of the adverse outcome was examined in each subgroup of women with asthma compared with the control group using Review Manager (Version 4.2.7, Wintertree Software Inc). A fixed effects model was used since there was no significant heterogeneity between studies ($\chi^2$ test for heterogeneity, $p>0.05$). The difference between relative risks for the exacerbation and no exacerbation subgroups was determined using the method of Altman and Bland.

Overall, four studies met the criteria for inclusion. The quality of the included studies was assessed using an adaptation of the checklist outlined by Duckitt and Harrington. Points were scored for participant selection (1 point if the cohort was representative of the general pregnant population, 0 points if cohort was a selected group, or selection not described), comparability of groups (2 points if there were no differences between the groups, particularly in age, parity and smoking status or if differences were adjusted for, 1 point if differences were not recorded and 0 points if groups differed), outcome definition (1 point for acceptable
Asthma exacerbations during pregnancy

Table 3 Quality assessment of non-randomised studies included in meta-analyses

<table>
<thead>
<tr>
<th></th>
<th>Gordon et al11</th>
<th>Jana et al15</th>
<th>Schatz et al12</th>
<th>Stenius-Aarniala et al13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant selection</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Comparability between groups</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Outcome definition</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Outcome diagnosis</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Sample size</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Cohort design</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total score</td>
<td>3</td>
<td>8</td>
<td>8</td>
<td>6</td>
</tr>
</tbody>
</table>

Exacerbation during pregnancy

<table>
<thead>
<tr>
<th></th>
<th>Asthma n/N</th>
<th>Control n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al 1970</td>
<td>2/10</td>
<td>5555/30861</td>
</tr>
<tr>
<td>Jana et al 1995</td>
<td>3/15</td>
<td>42/370</td>
</tr>
<tr>
<td>Schatz et al 1995</td>
<td>3/54</td>
<td>1/54</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Asthma n/N</th>
<th>Control n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al 1970</td>
<td>36/255</td>
<td>5555/30861</td>
</tr>
<tr>
<td>Jana et al 1995</td>
<td>21/169</td>
<td>42/370</td>
</tr>
<tr>
<td>Schatz et al 1995</td>
<td>20/431</td>
<td>13/431</td>
</tr>
</tbody>
</table>

No exacerbation during pregnancy

Exacerbation during pregnancy

<table>
<thead>
<tr>
<th></th>
<th>Asthma n/N</th>
<th>Control n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al 1970</td>
<td>38/255</td>
<td>3518/30861</td>
</tr>
<tr>
<td>Jana et al 1995</td>
<td>28/169</td>
<td>76/370</td>
</tr>
<tr>
<td>Schatz et al 1995</td>
<td>16/431</td>
<td>11/431</td>
</tr>
</tbody>
</table>

No exacerbation during pregnancy

<table>
<thead>
<tr>
<th></th>
<th>Asthma n/N</th>
<th>Control n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al 1970</td>
<td>13/237</td>
<td>1/54</td>
</tr>
<tr>
<td>Jana et al 1995</td>
<td>13/431</td>
<td>1/54</td>
</tr>
</tbody>
</table>

Figure 1 Meta-analysis examining the risk of low birth weight infants from asthmatic and non-asthmatic (control) pregnancies. Studies are grouped according to whether women had or did not have an exacerbation of asthma during pregnancy. The relative risks (RR) with 95% confidence intervals are given.

<table>
<thead>
<tr>
<th></th>
<th>Asthma n/N</th>
<th>Control n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al 1970</td>
<td>13/237</td>
<td>1/54</td>
</tr>
<tr>
<td>Jana et al 1995</td>
<td>13/431</td>
<td>1/54</td>
</tr>
</tbody>
</table>

Figure 2 Meta-analysis examining the risk of preterm delivery from asthmatic and non-asthmatic (control) pregnancies. Studies are grouped according to whether women had or did not have an exacerbation of asthma during pregnancy. The relative risks (RR) with 95% confidence intervals are given.

Exacerbations of asthma during pregnancy and the risk of low birth weight

Using data from three studies,11 12 26 there was a significantly increased risk for low birth weight in women who had an asthma exacerbation during pregnancy (relative risk (RR) 2.54, 95% confidence interval (CI) 1.52 to 4.25) compared with women without asthma (fig 1). There was no increased risk for low birth weight in asthmatic women who did not have an exacerbation during pregnancy (RR 1.12, 95% CI 0.89 to 1.40) compared with women without asthma. The difference between the relative risks of the exacerbation and no exacerbation subgroups was also significant (ratio of relative risk (RRR) 2.27, 95% CI 1.29 to 3.97).13

Exacerbations of asthma during pregnancy and the risk of preterm delivery

Using data from four studies,11–13 26 there was no significantly increased risk of preterm delivery in women who had an exacerbation of asthma during pregnancy (RR 1.46, 95% CI 0.77 to 2.78) or in women who did not have an asthma exacerbation (RR 1.17, 95% CI 0.57 to 2.43).
but smaller increase in the risk of preterm delivery, and a
found a doubling of the risk of low birth weight, a significant
control study identified that asthma severity and control
pre-eclampsia as an outcome is small, there appears to be
may contribute to alterations in uteroplacental blood flow 21
example, changes in vascular hyperreactivity with asthma
Other pathogenetic factors may also be playing a role. For
Using data from two studies (fig 3), 12 13 there was no
difference between the relative risks for the subgroups with
compared with women without asthma (fig 2). There was no
exacerbation during pregnancy (RR 0.93, 95% CI 0.74 to 1.17)
3.01 (1.69, 4.94)
1.41 (0.95, 2.09)
1.34 (0.47, 3.87)
1.40 (0.48, 4.10)
1.37 (0.65, 2.92)
1.17 (0.73, 1.86)
2.01 (1.16, 3.46)
1.15 (0.59, 2.24)
1.34 (0.47, 3.87)
1.48 (1.07, 2.04)
0.1 0.2 0.5 1 2 5 10
Relative risk of pre-eclampsia compared to women without asthma
(95% confidence interval)

Figure 3 Meta-analysis examining the risk of pre-eclampsia from
asthmatic and non-asthmatic (control) pregnancies. Studies are grouped
based on whether women had or did not have an exacerbation during
pregnancy. The relative risks (RR) with 95% confidence intervals are
given.

exacerbation during pregnancy (RR 0.93, 95% CI 0.74 to 1.17)
compared with women without asthma (fig 2). There was no
difference between the relative risks for the subgroups with
or without exacerbations (RRR 1.57, 95% CI 0.80 to 3.1).13

Exacerbations of asthma during pregnancy and the
risk of pre-eclampsia
Using data from two studies (fig 3), 12 13 there was no increased risk of pre-eclampsia among women who had an
asthma exacerbation during pregnancy (RR 1.37, 95% CI 0.65 to 2.92); rather, there was a significantly increased risk of pre-eclampsia in asthmatic women who did not have a severe
exacerbation during pregnancy compared with women with
out asthma (RR 1.48, 95% CI 1.07 to 2.04). However, the
difference between the relative risks was not significant (RRR 0.91, 95% CI 0.40 to 2.09).

In summary, having an exacerbation of asthma during
pregnancy was associated with an increased risk for low birth
weight, but not preterm delivery or pre-eclampsia. This relationship had a similar effect size to that of maternal
smoking during pregnancy, which doubles the risk of low
birth weight.12 The mechanisms for the effect of exacerbations
on low birth weight are unknown, but may include a
direct effect of fetal hypoxia on growth, or changes in fetal
growth via reduced uteroplacental blood flow or other
alterations in placental function.12 Future studies will need
to consider the issue of maternal smoking more carefully, as
only one study included in the meta-analysis considered possible confounding by smoking, with control and asth-
matic subjects matched for smoking status.12 A recent report
found a doubling of the risk of low birth weight, a significant
but smaller increase in the risk of preterm delivery, and a
significantly reduced risk of pre-eclampsia among smokers.13

We speculate that the lack of association between exacerbations and preterm delivery may be due to confound-
ing by treatment with oral steroids which has previously been
associated with preterm delivery in several large prospective
cohort studies. 10 11 While the number of studies investigating
pre-eclampsia as an outcome is small, there appears to be
some evidence that the underlying inflammatory disease of
asthma may be involved, since women without exacerbation
were more at risk of pre-eclampsia, and a recent large case-
control study identified that asthma severity and control
before pregnancy may be associated with an increased risk.14
Other pathogenetic factors may also be playing a role. For
example, changes in vascular hyperreactivity with asthma
may contribute to alterations in uteroplacental blood flow22
with consequences for the development of pre-eclampsia.
Studies of the placenta from asthmatic pregnancies have
indicated that there are changes in in vitro vascular responses
to both dilator and constrictor agents in women with
moderate and severe asthma in the absence of changes in
fetal growth.34 The responses observed in the perfused
placenta from moderate and severe asthmatics were similar
to those previously observed in women with pre-eclampsia.37

TREATMENT OF EXACERBATIONS DURING
PREGNANCY
A study from the United States found that pregnant women
presenting to the emergency department with an asthma exacerbation were significantly less likely to be given oral
steroids either in the emergency department or on discharge
from hospital than non-pregnant women.38 The pregnant
women were also three times more likely than non-pregnant
women to report an ongoing asthma exacerbation following
discharge.3 It is important that treatment should be
maximised during any asthma exacerbation which occurs
during pregnancy. A severe asthma attack presents more of
a risk to the fetus than the use of asthma medications due to
the potential reduction in the oxygen supply to the fetus.15 In
the event of an asthma emergency, women should receive
close monitoring of lung function, oxygen saturation should
be maintained above 95%, and fetal monitoring should be
considered.39 In cases of severe asthma close cooperation
between the respiratory specialist and obstetrician is essen-
tial.39

There have been two randomised controlled trials of
asthma treatment during pregnancy. Wandel et al40 studied
84 women who had 105 exacerbations during pregnancy. At
the time of admission all women who were hospitalised were
randomised to receive intravenous aminophylline and
methylprednisolone (n = 33) or methylprednisolone alone
(n = 32). There was no difference in the length of hospital
stay between treatments, but more side effects were reported
in women given aminophylline.39 The women were further
randomised on discharge to receive inhaled b2 agonist with
either oral steroid taper alone (40 mg reduced by 8 mg daily,
n = 31) or ICS (beclomethasone) plus oral steroid taper
(n = 34). One third of the women required readmission for
subsequent exacerbations; however, the inclusion of ICS on
discharge reduced the readmission rate by 55%.40

A double blind, double placebo controlled randomised trial
from 1995 to 2000 compared the use of inhaled beclometha-
sone and oral theophylline for the prevention of asthma
exacerbations requiring medical intervention (hospitalisation,
unscheduled visit to doctor or emergency department, or
oral steroid use) in pregnant women with moderate asthma.41

Patients were randomised to the treatments up to 26 weeks
gestation, which may have included some patients who were
at reduced risk of an exacerbation due to their gestational
age. In fact, subjects were excluded if they had severe or
unstable asthma which had resulted in a hospital admission
from 1995 to 2000 compared the use of inhaled beclometha-
sone and oral theophylline for the prevention of asthma
exacerbations requiring medical intervention (hospitalisation,
unscheduled visit to doctor or emergency department, or
oral steroid use) in pregnant women with moderate asthma.41

www.thoraxjnl.com
medications such as fluticasone or combination therapy with long acting beta agonists for asthma during pregnancy.

An historical cohort study compared inhaled beclomethasone, oral theophylline, and inhaled triamcinolone acetonide use for asthma during pregnancy and determined the number of subjects admitted to hospital with an asthma exacerbation during pregnancy. There were significantly more hospital admissions among women using beclomethasone (79%) than in those using triamcinolone (33%) or theophylline (28%), and a significantly higher proportion of beclomethasone users required oral steroids during pregnancy. However, the results of this study should be interpreted with caution as the numbers of patients in each of the treatment groups was small (15 triamcinolone, 14 beclomethasone, and 25 theophylline). In addition, 50% of the subjects in the beclomethasone group and 27% of the subjects in the triamcinolone group also used theophylline during pregnancy.14

A prospective cohort study found that the risk of exacerbations of asthma during pregnancy was reduced by the use of ICS medication.15 Only 34% of women used ICS prior to an acute asthma attack while 62% of women who did not have an acute attack were using ICS during pregnancy. Following the exacerbation, 94% of women used ICS and 74% were treated with oral corticosteroids.15 Similar data have been reported recently by Schatz and Liebman, suggesting the importance of women using appropriate preventer medication for asthma control during pregnancy.16

There are few randomised controlled trials of treatments for asthma during pregnancy. However, pregnant women should receive vigorous treatment of an exacerbation during pregnancy to reduce the risk of readmission and to improve outcomes for the fetus. Recent US guidelines for the management of asthma during pregnancy recommend a stepwise approach to treatment with the goal of maintaining control of maternal asthma, as the risks of asthma exacerbations are greater than the risks associated with the use of asthma medications during pregnancy.17

CONCLUSIONS
Exacerbations occur in approximately 20% of all pregnant women with asthma and this rate is greatly increased in women with severe asthma. The mechanisms which lead to asthma exacerbations during pregnancy are poorly understood; however, viral infections and discontinuation of anti-inflammatory medications may play a role. Asthma exacerbations require appropriate treatment in order to protect the fetus as far as possible from adverse outcomes. In particular, the fetus is at risk of being born of low birth weight, which may predispose to diseases in later life. Advancements in the pharmacotherapy and management of asthma during pregnancy have the potential to improve health outcomes for both mother and baby.

Authors’ affiliations
V E Murphy, P G Gibson, Department of Respiratory and Sleep Medicine, John Hunter Hospital and Hunter Medical Research Institute, University of Newcastle, NSW 2310, Australia
V L Clifton, Mothers and Babies Research Centre, Hunter Medical Research Institute, University of Newcastle, NSW 2310, Australia
Dr Vanessa Murphy was the recipient of a Hunter Medical Research Institute/Port Waratah Coal Services Postdoctoral Fellowship. Conjoint Professor Peter Gibson is an NHMRC Practitioner Fellow. Dr Vicki Clifton was the recipient of the Arthur Wilson Memorial Scholarship from the Royal Australian College of Obstetricians and Gynaecologists and NHMRC Career Development grant (ID 300786).

The authors have no competing interests.

REFERENCES

www.thoraxjnl.com
LUNG ALERT

Sildenafil is useful in pulmonary arterial hypertension


Many recent studies, most of them uncontrolled trials, suggest that sildenafil may be beneficial in the treatment of pulmonary arterial hypertension (PAH). A multicentre, double blind, placebo controlled study was performed in 278 patients with symptomatic PAH (either idiopathic, associated with connective tissue disease, or repaired systemic-to-pulmonary shunts). The patients were randomised into four treatment groups: placebo, 20 mg, 40 mg, and 80 mg sildenafil three times daily. The primary measure of efficacy was the change from baseline to week 12 in the distance walked in 6 minutes. An increase in the 6 minute walk distance was observed in all sildenafil groups, the mean placebo corrected treatment effects being 45 m (+13.0%), 46 m (+13.3%), and 50 m (+14.7%) with 20 mg, 40 mg, and 80 mg sildenafil, respectively (all p<0.001).

Cardiopulmonary haemodynamics and the WHO functional status also improved significantly with all doses of sildenafil. However, there was no statistical difference in the incidence of clinical worsening. With all doses of sildenafil, most adverse events observed were mild to moderate in severity and there were no significant changes in laboratory variables. This study was not, however, designed to address the important end point of mortality.

R L Karadi
Clinical Fellow, Hope Hospital, Salford, UK; klranga@hotmail.com